eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive About the journal Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 105
Review paper

Antinuclear antibodies in systemic sclerosis associated with increased risk of malignancy

Anna Stochmal, Marta Sar-Pomian, Joanna Czuwara, Lidia Rudnicka

Dermatol Rev/Przegl Dermatol 2018, 105, 604–612
Online publish date: 2018/11/08
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Patients with systemic sclerosis are at 1.5–5-fold increased risk of developing malignant diseases. It has been shown that some types of antinuclear antibodies associated with systemic sclerosis may have predictive value for development of malignant diseases in patients with systemic sclerosis. Patients with circulating anti-RNA polymerase III antibodies (RNAP) are at significantly increased risk of developing a malignant disease (breast cancer, followed by leukemias and gastrointestinal or gynecologic cancers) within 36 months from the onset of the disease (OR = 7.38). Thus, regular cancer screening is recommended in anti-RNAP III-positive patients. An increased prevalence of lung cancer was reported in patients with circulating anti-topoisomerase I antibodies (11.4%) compared to the median of 2.4% in all patients with systemic sclerosis. Among patients with circulating anti-centromere antibodies, individuals who are anti-CENP-F-positive are at increased risk of developing breast cancer or lung cancer. Anti-PM-Scl antibodies and anti-Ku antibodies are rare in systemic sclerosis, but may have some association with increased risk of malignancy in these patients as well. Thus, recent data indicate that in patients with systemic sclerosis, diverse disease-specific antinuclear antibodies may be associated with increased risk of developing malignant tumors and require especially careful preventive cancer screening.

systemic sclerosis, malignancy, cancer, antinuclear antibodies

Steen V.D.: Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35, 35-42.
Mehra S., Walker J., Patterson K. Fritzler M.J.: Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12, 340-354.
Knobler R., Moinzadeh P., Hunzelmann N., Kreuter A., Cozzio A., Mouthon L., et al.: European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. J Eur Acad Dermatol Venereol 2017, 31, 1401-1424.
Krasowska D., Rudnicka L., Dańczak-Pazdrowska A., Chodorowska G., Woźniacka A., Lis-Święty A., et al.: Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1: diagnosis and monitoring. Dermatology Review/Przegląd Dermatologiczny 2017, 104, 483-498.
Vlagea A., Falagan S., Gutierrez-Gutierrez G., Moreno-Rubio J., Merino M., Zambrana F., et al.: Antinuclear antibodies and cancer: a literature review. Crit Rev Oncol Hematol 2018, 127, 42-49.
Moinzadeh P., Nihtyanova S.I., Howell K., Ong V.H. Denton C.P.: Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol 2012, 43, 249-255.
Imran A., Neelam F. Tariq M.: Incidence of circulating antinuclear antibodies in cancer patients. Indian J Med Sci 2003, 57, 113-116.
Szekanecz E., Andras C., Sandor Z., Antal-Szalmas P., Szanto J., Tamasi L., et al.: Malignancies and soluble tumor antigens in rheumatic diseases. Autoimmun Rev 2006, 6, 42-47.
Sargin G., Senturk T. Cildag S.: Systemic sclerosis and malignancy. Int J Rheum Dis 2018, 21, 1093-1097.
Szekanecz Z., Szekanecz E., Bako G. Shoenfeld Y.: Malignancies in autoimmune rheumatic diseases – a mini-review. Gerontology 2011, 57, 3-10.
Abu-Shakra M., Guillemin F. Lee P.: Cancer in systemic sclerosis. Arthritis Rheum 1993, 36, 460-464.
Olesen A.B., Svaerke C., Farkas D.K. Sorensen H.T.: Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010, 163, 800-806.
Szekanecz E., Szamosi S., Horvath A., Nemeth A., Juhasz B., Szanto J., et al.: Malignancies associated with systemic sclerosis. Autoimmun Rev 2012, 11, 852-855.
Kasifoglu T., Yasar Bilge S., Yildiz F., Ozen G., Pehlivan Y., Yilmaz N., et al.: Risk factors for malignancy in systemic sclerosis patients. Clin Rheumatol 2016, 35, 1529-1533.
Lu T.Y., Hill C.L., Pontifex E.K., Roberts-Thomson P.J.: Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study. Rheumatol Int 2008, 28, 895-899.
Asten P., Barrett J. Symmons D.: Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999, 26, 1705-1714.
Shah A.A., Hummers L.K., Casciola-Rosen L., Visvanathan K., Rosen A. Wigley F.M.: Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol 2015, 67, 1053-1061.
Sobanski V., Dauchet L., Lefevre G., Lambert M., Morell-Dubois S., Sy T., et al.: Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol 2014, 66, 407-417.
Denton C.P., Steen V.: Scleroderma renal crisis. [in] Scleroderma: From Pathogenesis to Comprehensive Management. Varga J., Denton C.P., Wigley F.M. (eds.). Springer US Boston, MA, 2012, 361-371.
Airo P., Ceribelli A., Cavazzana I., Taraborelli M., Zingarelli S. Franceschini F.: Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011, 38, 1329-1334.
Moinzadeh P., Fonseca C., Hellmich M., Shah A.A., Chighizola C., Denton C.P., et al.: Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014, 16, R53.
Saigusa R., Asano Y., Nakamura K., Miura S., Ichimura Y., Takahashi T., et al.: Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis. J Dermatol 2015, 42, 524-527.
Lazzaroni M.G., Cavazzana I., Colombo E., Dobrota R., Hernandez J., Hesselstrand R., et al.: Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. J Rheumatol 2017, 44, 639-647.
Shah A.A., Rosen A., Hummers L., Wigley F., Casciola-Rosen L.: Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010, 62, 2787-2795.
Joseph C.G., Darrah E., Shah A.A., Skora A.D., Casciola-Rosen L.A., Wigley F.M., et al.: Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014, 343, 152-157.
Shah A.A., Casciola-Rosen L., Rosen A.: Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 2015, 67, 317-326.
Teng M.W., Smyth M.J.: Cancer. Can cancer trigger autoimmunity? Science 2014, 343, 147-148.
Poormoghim H., Moghadam A.S., Moradi-Lakeh M., Jafarzadeh M., Asadifar B., Ghelman M., et al.: Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int 2013, 33, 1943-1950.
Douvas A.S., Achten M., Tan E.M.: Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979, 254, 10514-10522.
Hanke K., Dahnrich C., Bruckner C.S., Huscher D., Becker M., Jansen A., et al.: Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009, 11, R28.
Colaci M., Giuggioli D., Sebastiani M., Manfredi A., Vacchi C., Spagnolo P., et al.: Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev 2013, 12, 374-379.
Onishi A., Sugiyama D., Kumagai S., Morinobu A.: Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013, 65, 1913-1921.
Hudson M., Mahler M., Pope J., You D., Tatibouet S., Steele R., et al.: Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012, 39, 787-794.
Rattner J.B., Rees J., Whitehead C.M., Casiano C.A., Tan E.M., Humbel R.L., et al.: High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med 1997, 20, 308-319.
Higuchi M., Horiuchi T., Ishibashi N., Yoshizawa S., Niho Y. Nagasawa K.: Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 2000, 19, 123-126.
Launay D., Le Berre R., Hatron P.Y., Peyrat J.P., Hachulla E., Devulder B., et al.: Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004, 23, 516-522.
Schilders G., van Dijk E., Raijmakers R. Pruijn G.J.: Cell and molecular biology of the exosome: how to make or break an RNA. Int Rev Cytol 2006, 251, 159-208.
Melo S.A., Sugimoto H., O’Connell J.T., Kato N., Villanueva A., Vidal A., et al.: Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 2014, 26, 707-721.
Azmi A.S., Bao B., Sarkar F.H.: Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev 2013, 32, 623-642.
Brouwer R., Hengstman G.J., Vree Egberts W., Ehrfeld H., Bozic B., Ghirardello A., et al.: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001, 60, 116-123.
Marie I., Lahaxe L., Benveniste O., Delavigne K., Adoue D., Mouthon L., et al.: Long-term outcome of patients with polymyositis/ dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010, 162, 337-344.
Cabrera C.M., Fernandez-Grande E., Urra J.M.: Serological profile and clinical features of nucleolar antinuclear pattern in patients with systemic lupus erythematosus from southwestern Spain. Lupus 2016, 25, 980-987.
Bernal-Bello D., de Tena J.G., Guillen-Del Castillo A., Selva-O’Callaghan A., Callejas-Moraga E.L., Marin-Sanchez A.M., et al.: Novel risk factors related to cancer in scleroderma. Autoimmun Rev 2017, 16, 461-468.
Mimori T.: Clinical significance of anti-Ku autoantibodies: a serologic marker of overlap syndrome? Intern Med 2002, 41, 1096-1098.
Cavazzana I., Ceribelli A., Quinzanini M., Scarsi M., Airo P., Cattaneo R., et al.: Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus 2008, 17, 727-732.
Cavazzana I., Fredi M., Taraborelli M., Quinzanini M., Tincani A., Franceschini F.: A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. Clin Exp Rheumatol 2013, 31, 118-121.
Hoa S., Hudson M., Troyanov Y., Proudman S., Walker J., Stevens W., et al.: Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltimore) 2016, 95, e4713.
Tyndall A.J., Bannert B., Vonk M., Airo P., Cozzi F., Carreira P.E., et al.: Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010, 69, 1809-1815.
Kuo C.F., Luo S.F., Yu K.H., Chou I.J., Tseng W.Y., Chang H.C., et al.: Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2012, 41, 44-49.
Roumm A.D., Medsger T.A. Jr.: Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum 1985, 28, 1336-1340.
Hashimoto A., Arinuma Y., Nagai T., Tanaka S., Matsui T., Tohma S., et al.: Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis. Intern Med 2012, 51, 1683-1688.
Derk C.T., Rasheed M., Artlett C.M. Jimenez S.A.: A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006, 33, 1113-1116.
Hill C.L., Nguyen A.M., Roder D., Roberts-Thomson P.: Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003, 62, 728-731.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe